HealthInvest 2024
Morgans, investor relations firm IR Department and * teamed up to host HealthInvest 2024 in Sydney this week, with the event showcasing some of the ASX’s leading and up-and-coming health and life sciences companies.
Power said it was a good opportunity for both professional and retail investors to hear directly from key industry players.
ImpediMed ‘hiting their straps’
Power said ImpediMed (ASX:IPD) CEO and managing director Dr Parmjot Bains made the point that with a new board and management team the company was starting to make strong progress.
IPD’s SOZO digital health platform incorporates its trademarked L-Dex technology and bioimpedance spectroscopy (BIS) to non-invasively, accurately and quickly measure and monitor fluid status.
SOZO is FDA-cleared, CE-marked, and ARTG-listed for various conditions, including lymphoedema, heart failure, and protein-calorie malnutrition, and is available in select global markets.
It is the only US FDA-cleared, clinically validated BIS device for early detection and prevention of lymphoedema.
BIS, for preventing breast cancer-related lymphoedema, is now included in the globally recognised guidelines of the National Comprehensive Cancer Network and the Multinational Association of Supportive Care in Cancer.
“They’re really starting to hit their straps now,” Power said.
“Bains joined in January and the focus is on targeting key states in the US to build the installed base of the SOZO device.
“She told us that momentum is picking up, so that is a good sign.”
IPD Price at posting:
5.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)